Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs AMOXICILLIN AND CLAVULANATE POTASSIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Mild to moderate pain,Fever
Lower respiratory tract infections,Acute bacterial sinusitis,Otitis media,Urinary tract infections,Skin and skin structure infections,Bone and joint infections,Intra-abdominal infections,Dental infections
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Amoxicillin undergoes partial hepatic metabolism via hydrolysis. Clavulanate is extensively metabolized in the liver, primarily by hydrolysis and conjugation.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Amoxicillin: ~20% (mainly albumin); Clavulanate: ~25% (albumin).
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Amoxicillin: ~0.3-0.4 L/kg; Clavulanate: ~0.3 L/kg. Distributes into tissues, not CSF unless inflamed.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral: ~80-90% for amoxicillin; ~60-75% for clavulanate. Enhanced with food.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
For Cr Cl 10-30 m L/min: 250-500 mg amoxicillin component every 12 hours. For Cr Cl <10 m L/min: 250-500 mg amoxicillin component every 24 hours. Hemodialysis: 250-500 mg every 24 hours, give additional dose during and after dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
No specific dose adjustment recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh C); consider alternative therapy or reduced dosing, but no formal guidelines.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
For children >3 months: 25-45 mg/kg/day of amoxicillin component divided every 12 hours (based on 200 mg/28.5 mg per 5 m L suspension) or 20-40 mg/kg/day divided every 8 hours (based on 125 mg/31.25 mg per 5 m L suspension). For severe infections, up to 90 mg/kg/day of amoxicillin component divided every 12 hours (using 400 mg/57 mg per 5 m L suspension).
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Initiate at lower end of dosing range due to increased risk of renal impairment. Monitor renal function and adjust dose based on creatinine clearance as per renal adjustment guidelines.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
No FDA boxed warning.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome) in patients with penicillin allergy,Clostridioides difficile-associated diarrhea,Hepatic toxicity (elevated liver enzymes, hepatitis, cholestatic jaundice) more common in elderly and with prolonged use,Renal impairment requires dose adjustment,Risk of superinfection with prolonged therapy,Skin rash can occur in patients with mononucleosis
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
History of anaphylactic reaction to penicillins or cephalosporins,Previous cholestatic jaundice or hepatic dysfunction associated with amoxicillin-clavulanate,Concurrent use with disulfiram or probenecid (relative)
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
May be taken with or without food; food enhances absorption; avoid ingestion with high-dose clavulanate? (no significant interaction); no specific food restrictions; milk-containing products do not interact significantly.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Use during first trimester is considered safe if clinically indicated. During second and third trimesters, no known fetal risks. However, avoid use near term due to potential for neonatal kernicterus (theoretical risk from high doses, but not confirmed).
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Amoxicillin and clavulanate are excreted into breast milk in low concentrations. M/P ratio not established. Considered compatible with breastfeeding by AAP; risk of infant sensitization, diarrhea, or thrush. Use with caution in infants with history of penicillin allergy.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Pharmacokinetic changes in pregnancy (increased renal clearance, expanded plasma volume) may require dose adjustments: total daily dose typically remains same but dosing interval may need to be shortened (e.g., every 6-8 hours instead of every 12 hours) for severe infections; monitor clinical response. No standard recommendation for routine adjustment; base on severity and renal function.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Use weight-based dosing for pediatric patients; reconstitute oral suspension with appropriate amount of water; administer at start of meal to reduce GI upset; check renal function before dosing; avoid in patients with mononucleosis due to risk of maculopapular rash; higher doses of clavulanate may cause diarrhea; intravenous infusion over 30-40 minutes; consider penicillin allergy cross-reactivity; not effective against MRSA; requires dose adjustment in Cr Cl <30 m L/min.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take this medication exactly as prescribed, usually every 12 hours.,Take with food to reduce stomach upset and improve absorption.,Complete the full course even if you feel better.,Shake the oral suspension well before each use.,Store oral suspension in refrigerator, discard after 10 days.,Report severe diarrhea, rash, or signs of allergy immediately.,May cause diarrhea; do not treat without consulting doctor.,Inform your doctor if you are pregnant, breastfeeding, or have liver disease.
No interactions on record
"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."
"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."
"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs AMOXICILLIN AND CLAVULANATE POTASSIUM, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. AMOXICILLIN AND CLAVULANATE POTASSIUM is a Penicillin Antibiotic that works by Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and AMOXICILLIN AND CLAVULANATE POTASSIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of AMOXICILLIN AND CLAVULANATE POTASSIUM is: 500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and AMOXICILLIN AND CLAVULANATE POTASSIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. AMOXICILLIN AND CLAVULANATE POTASSIUM is classified as Category A/B. Amoxicillin-clavulanate is pregnancy category B. No evidence of teratogenicity in animal studies; human data do not demonstrate increased risk of major congenital malformations. Us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.